Look at the FACTS...ignore GARBAGEA lof has happend for MARI in the month of April....they are making great progress to acheive their goals. It's the market risk that is pulling MARI down, and the same is said to other cannabis related stocks.
Manipulation is NOT happening (get this out of your head)...and look at the FACTS
However, if you look at the recent weeks, MARI has gone down more slowly then the likes of others, as they have acheived these miletsones. In addition, if you look at the short data, the % shorted YTD has decreased.
FACTS: - Partnership with Mckesson and Lovell Drugs...(Yes I said Mckesson, if you did your due diligence you would have found this)
- Vesisorb allows for fat soluble materials to mix well with water...which means more of the cannabinoids are entering the blood stream. So Vesisorb increases the bioavailability which reduces the need for API (active pharmaceutical ingredients) which will help save costs. If you read the news, API generally come from China, and the prices for these API have gone up tremendously
- Re-read the "God Damn Financials AGAIN"...If you did this you will notice that MARI had oil extract sales that accounted for 28% of revenues compared to the indsutry 15%...which means higher margins and higher sales per gram that MARI can obtain. Also, the higher then expected losses were due to accounting of "Financial Assets" from equity to fair value for profit and loss...which means that given the higher volatility associated with the "Convertible Debentures" they had to re-classify this as "Held For Trading", which means any changes in value for the debenture must be recorded on the Income Statement. Again....this was a one time accounting charge in FY 2017. Also, if you look at the overall expenses...they increased expenses by $10 Mil from Q2 2017 to Q4 2017 for strategic reasons related to bring on more experienced people who can EXECUTE on objectives/milestones, optimization of production facility to reduce costs, and roll out the pharmacy initiatives. If you look at the "Team Members" you will notice Veronica Lesch "Pharmacy Project Management"
I think people are over their heads about manipulation and Clay Horner/Boner (whatever)...Investors need to place more emphasizes on growth of MARI then the actual financials at this point. MARI is poised for growth
Stay true to the FACTS, and ignore GARBAGE such as price manipulation or other bullshit people make up.
Do a little bit of common sense and due diligence, and you will find all this information and FACTS that will poise MARI for growth. Again, MARI is focusing on the LT objective, they realize that the industry will go to a "Wholesale" model which mean dry cannabis will be selling for around $5 per gram, but given the higher sales mix of oil extract, and a keen focus on reducing costs, they will be able to better preserve margins from the decline in prices from the wholesale model.
Best,
Maricann Shareholder